Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11251 - 11275 of 11637 in total
Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 …
Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)).
Investigational
Matched Description: … Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With …
NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled heparin.
Investigational
Matched Description: … It is a technetium-99m radiolabeled [heparin]. …
Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. It was in trials for depression in the 1970s but never marketed.
Experimental
Matched Description: … Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. …
Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123. It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
Investigational
Matched Description: … It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute …
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).
Investigational
Matched Description: … Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting …
Investigational
Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment. Verubecestat is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. In the study,...
Investigational
Matched Description: … In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent ... and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of …
Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. Eprotirome increases the body’s energy consumption and reduces body weight and markedly reduces blood lipids and blood glucose.
Investigational
Matched Description: … Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. …
Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.
Vet approved
Matched Description: … Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal …
GS-6620 is under investigation in clinical trial NCT01316237 (A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection).
Investigational
Matched Description: … GS-6620 is under investigation in clinical trial NCT01316237 (A Study Evaluating the Safety, Tolerability …
JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma).
Investigational
Matched Description: … JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to …
SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70. SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).
Investigational
Matched Description: … SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients …
Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder).
Investigational
Matched Description: … Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety …
BPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects).
Investigational
Matched Description: … BPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 …
Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).
Investigational
Matched Description: … Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of …
Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants).
Investigational
Matched Description: … Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of …
MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).
Investigational
Matched Description: … MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics …
LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).
Investigational
Matched Description: … LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or …
Carotegrast methyl is under investigation in clinical trial NCT03531892 (A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis).
Investigational
Matched Description: … Carotegrast methyl is under investigation in clinical trial NCT03531892 (A Study to Evaluate the Safety …
CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
Investigational
Matched Description: … CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab …
mRNA-3351 is a modified mRNA encoding the UGT1A1 gene. Developed by Moderna, it is currently being investigated as the treatment for Crigler-Najjar syndrome
Experimental
Matched Description: … mRNA-3351 is a modified mRNA encoding the UGT1A1 gene. …
Dalosirvat is under investigation in clinical trial NCT03742518 (A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia).
Investigational
Matched Description: … Dalosirvat is under investigation in clinical trial NCT03742518 (A Study Evaluating the Efficacy and …
An ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells. It is a normal constituent of resting muscle and probably is in constant equilibrium with fructose-6-phosphate. (Stedman, 26th ed)
Experimental
Matched Description: … It is a normal constituent of resting muscle and probably is in constant equilibrium with fructose-6- …
IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer. It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.
Investigational
Matched Description: … It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific …
Displaying drugs 11251 - 11275 of 11637 in total